• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

公开获取 HIV-1 耐药性序列和治疗数据：系统评价。

Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review.

机构信息

Department of Medicine, Stanford University, Stanford, CA, USA.

Department of Medicine, Georgetown University, Washington, DC, USA.

出版信息

Lancet Microbe. 2022 May;3(5):e392-e398. doi: 10.1016/S2666-5247(21)00250-0. Epub 2022 Jan 19.

DOI:10.1016/S2666-5247(21)00250-0
PMID:35544100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9095989/
Abstract

HIV-1 pol sequences from antiretroviral therapy (ART)-naive and ART-experienced people living with HIV-1 are fundamental to understanding the genetic correlates and epidemiology of HIV-1 drug resistance (HIVDR). To assess the public availability of HIV-1 pol sequences and ART histories of the individuals from whom sequenced viruses were obtained, we performed a systematic review of PubMed and GenBank for HIVDR studies published between 2010 and 2019 that reported HIV-1 pol sequences. 934 studies met inclusion criteria, including 461 studies of ART-naive adults, 407 of ART-experienced adults, and 66 of ART-naive and ART-experienced children. Sequences were available for 317 (68·8%) studies of ART-naive individuals, 190 (46·7%) of ART-experienced individuals, and 45 (68·2%) of children. Among ART-experienced individuals, sequences plus linked ART histories were available for 82 (20·1%) studies. Sequences were available for 21 (29·2%) of 72 clinical trials. Among journals publishing more than ten studies, the proportion with available sequences ranged from 8·3% to 86·9%. Strengthened implementation of data sharing policies is required to increase the number of studies with available HIVDR data to support the enterprise of global ART in the face of emerging HIVDR.

摘要

从从未接受过抗逆转录病毒疗法 (ART) 和接受过 ART 的艾滋病毒感染者中获取的 HIV-1 pol 序列，对于了解 HIV-1 耐药性 (HIVDR) 的遗传相关性和流行病学至关重要。为了评估从获得测序病毒的个体中获取的 HIV-1 pol 序列和 ART 史的公开可用性，我们对 2010 年至 2019 年间发表的报告 HIV-1 pol 序列的 HIVDR 研究进行了系统的 PubMed 和 GenBank 文献检索。934 项研究符合纳入标准，包括 461 项针对未接受过 ART 的成年人的研究、407 项针对接受过 ART 的成年人的研究和 66 项针对未接受过 ART 和接受过 ART 的儿童的研究。有 317 项（68.8%）未接受过 ART 的个体研究、190 项（46.7%）接受过 ART 的个体研究和 45 项（68.2%）儿童研究可获得序列。在接受过 ART 的个体中，有 82 项（20.1%）研究可获得序列和相关的 ART 史。有 21 项（29.2%）临床试验可获得序列。在发表超过 10 项研究的期刊中，有可用序列的比例范围为 8.3%至 86.9%。需要加强数据共享政策的实施，以增加具有可用 HIVDR 数据的研究数量，从而支持在出现新的 HIVDR 时进行全球 ART 事业。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b338/9095989/e5fdcc87dcee/nihms-1787879-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b338/9095989/0ce9c69ddb4a/nihms-1787879-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b338/9095989/e5fdcc87dcee/nihms-1787879-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b338/9095989/0ce9c69ddb4a/nihms-1787879-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b338/9095989/e5fdcc87dcee/nihms-1787879-f0002.jpg

相似文献

1
Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review.公开获取 HIV-1 耐药性序列和治疗数据：系统评价。
Lancet Microbe. 2022 May;3(5):e392-e398. doi: 10.1016/S2666-5247(21)00250-0. Epub 2022 Jan 19.
2
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.成人慢性未抑制的HIV感染中的结构化治疗中断（STI）
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148.
3
Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.HIV 阳性合并隐球菌性脑膜炎患者早期与延迟抗逆转录病毒治疗的比较
Cochrane Database Syst Rev. 2018 Jul 24;7(7):CD009012. doi: 10.1002/14651858.CD009012.pub3.
4
Accuracy of measures for antiretroviral adherence in people living with HIV.抗逆转录病毒药物依从性测量在 HIV 感染者中的准确性。
Cochrane Database Syst Rev. 2022 Jul 25;7(7):CD013080. doi: 10.1002/14651858.CD013080.pub2.
5
Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.司他夫定、拉米夫定与奈韦拉平联合疗法治疗成人HIV感染和艾滋病
Cochrane Database Syst Rev. 2006 Apr 19;2006(2):CD004535. doi: 10.1002/14651858.CD004535.pub2.
6
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.用于降低人类免疫缺陷病毒感染母婴传播风险的抗逆转录病毒药物。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003510. doi: 10.1002/14651858.CD003510.pub2.
7
Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.成人慢性抑制性HIV感染中的结构化治疗中断（STI）
Cochrane Database Syst Rev. 2005 Oct 19(4):CD005482. doi: 10.1002/14651858.CD005482.
8
Characterizing the HIV care continuum among children and adolescents with HIV in eastern and southern Africa in the era of "Universal Test and Treat": A systematic review and meta-analysis.在“普遍检测与治疗”时代对东部和南部非洲感染艾滋病毒的儿童和青少年的艾滋病毒护理连续体进行特征描述：一项系统评价和荟萃分析。
J Int AIDS Soc. 2025 Jun;28(6):e26526. doi: 10.1002/jia2.26526.
9
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎：系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
10
Progressive resistive exercise interventions for adults living with HIV/AIDS.针对感染艾滋病毒/艾滋病的成年人的渐进性抗阻运动干预措施。
Cochrane Database Syst Rev. 2004 Oct 18(4):CD004248. doi: 10.1002/14651858.CD004248.pub2.

引用本文的文献

1
The rise of open data practices among bioscientists at the University of Edinburgh.爱丁堡大学的生物科学家们开放数据实践的兴起。
PLoS One. 2025 Jul 23;20(7):e0328065. doi: 10.1371/journal.pone.0328065. eCollection 2025.
2
Kinetic coevolutionary models predict the temporal emergence of HIV-1 resistance mutations under drug selection pressure.动力学共进化模型预测了 HIV-1 耐药突变在药物选择压力下的时间出现。
Proc Natl Acad Sci U S A. 2024 Apr 9;121(15):e2316662121. doi: 10.1073/pnas.2316662121. Epub 2024 Apr 1.
3
How to report and make sense of a new HIV-1 circulating recombinant form?

本文引用的文献

1
Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement.评估实施国际医学期刊编辑委员会数据共享声明要求后的数据共享情况。
JAMA Netw Open. 2021 Jan 4;4(1):e2033972. doi: 10.1001/jamanetworkopen.2020.33972.
2
Responsible, practical genomic data sharing that accelerates research.负责任、实用的基因组数据共享，加速研究。
Nat Rev Genet. 2020 Oct;21(10):615-629. doi: 10.1038/s41576-020-0257-5. Epub 2020 Jul 21.
3
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology.
如何报告并理解一种新的HIV-1流行重组型？
Front Microbiol. 2024 Feb 21;15:1343143. doi: 10.3389/fmicb.2024.1343143. eCollection 2024.
4
Strengthening and enhancing national antiretroviral drug resistance surveillance in Zimbabwe-A country that has reached UNAIDS 95-95-95 amongst adults.加强和提升津巴布韦的国家抗逆转录病毒药物耐药性监测——一个在成年人中实现了联合国艾滋病规划署95-95-95目标的国家。
Front Public Health. 2024 Feb 14;12:1346027. doi: 10.3389/fpubh.2024.1346027. eCollection 2024.
5
Current Perspectives in Antiviral Research.抗病毒研究的现状。
Int J Mol Sci. 2023 Sep 26;24(19):14555. doi: 10.3390/ijms241914555.
6
Recommendations on data sharing in HIV drug resistance research.艾滋病耐药性研究中数据共享的建议。
PLoS Med. 2023 Sep 22;20(9):e1004293. doi: 10.1371/journal.pmed.1004293. eCollection 2023 Sep.
7
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use.HIV 耐药性流行率或发生率研究检查表：原理和推荐用法。
Lancet HIV. 2023 Oct;10(10):e684-e689. doi: 10.1016/S2352-3018(23)00173-X. Epub 2023 Sep 13.
8
Rapid and visual identification of HIV-1 using reverse transcription loop-mediated isothermal amplification integrated with a gold nanoparticle-based lateral flow assay platform.利用逆转录环介导等温扩增与基于金纳米颗粒的侧向流动分析平台相结合，实现对HIV-1的快速可视化鉴定。
Front Microbiol. 2023 Jul 12;14:1230533. doi: 10.3389/fmicb.2023.1230533. eCollection 2023.
9
Prevalence and predictors of data and code sharing in the medical and health sciences: systematic review with meta-analysis of individual participant data.在医学和健康科学领域中，数据和代码共享的流行率及其预测因素：基于个体参与者数据的系统评价和荟萃分析。
BMJ. 2023 Jul 11;382:e075767. doi: 10.1136/bmj-2023-075767.
10
Contingency and Entrenchment of Drug-Resistance Mutations in HIV Viral Proteins.HIV 病毒蛋白中耐药突变的偶然性和僵化性。
J Phys Chem B. 2022 Dec 22;126(50):10622-10636. doi: 10.1021/acs.jpcb.2c06123. Epub 2022 Dec 9.
一种用于 SARS-CoV-2 谱系的动态命名建议，以辅助基因组流行病学研究。
Nat Microbiol. 2020 Nov;5(11):1403-1407. doi: 10.1038/s41564-020-0770-5. Epub 2020 Jul 15.
4
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.整合酶抑制剂耐药突变的监测用于传播的 HIV-1 药物耐药性。
J Antimicrob Chemother. 2020 Jan 1;75(1):170-182. doi: 10.1093/jac/dkz417.
5
Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017.全球、区域和国家艾滋病毒发病率、流行率和死亡率，1980-2017 年，并预测至 2030 年，为 195 个国家和地区：全球疾病、伤害和危险因素研究 2017 年的系统分析。
Lancet HIV. 2019 Dec;6(12):e831-e859. doi: 10.1016/S2352-3018(19)30196-1. Epub 2019 Aug 19.
6
A systematic review of the genetic mechanisms of dolutegravir resistance.多替拉韦耐药的遗传机制的系统评价。
J Antimicrob Chemother. 2019 Nov 1;74(11):3135-3149. doi: 10.1093/jac/dkz256.
7
Effect of impact factor and discipline on journal data sharing policies.影响因子和学科对期刊数据共享政策的影响。
Account Res. 2019 Apr;26(3):139-156. doi: 10.1080/08989621.2019.1591277. Epub 2019 Mar 25.
8
Nextstrain: real-time tracking of pathogen evolution.Nextstrain：实时追踪病原体进化。
Bioinformatics. 2018 Dec 1;34(23):4121-4123. doi: 10.1093/bioinformatics/bty407.
9
Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors.临床试验的数据共享声明：医学期刊编辑国际委员会的一项要求。
PLoS Med. 2017 Jun 5;14(6):e1002315. doi: 10.1371/journal.pmed.1002315. eCollection 2017 Jun.
10
Reproducible and reusable research: are journal data sharing policies meeting the mark?可重复和可再利用的研究：期刊数据共享政策达标了吗？
PeerJ. 2017 Apr 25;5:e3208. doi: 10.7717/peerj.3208. eCollection 2017.